ECT2 amplification and overexpression as a new prognostic biomarker for early-stage lung adenocarcinoma.
Bottom Line: To examine gene abnormalities, 83 cases of various types of lung carcinoma were examined by quantitative real-time genomic PCR and immunohistochemistry.These results were verified using another set of early-stage adenocarcinomas resected at another hospital.Abnormality of the ECT2 gene occurs at a relatively early stage of lung adenocarcinogenesis and would be applicable as a new biomarker for prognostication of patients with lung adenocarcinoma.
Affiliation: Department of Pathology, Graduate School of Comprehensive Human Sciences, University of Tsukuba, Ibaraki, Japan.Show MeSH
Related in: MedlinePlus
Mentions: The seven selected gene amplifications were examined using 15 AIS (Type A or B) and 17 early-invasive adenocarcinomas (Type D or E) by qPCR (Fig. 1a). All seven genes showed amplification in early-invasive adenocarcinomas, confirming the results of Cancer Array-800. However, several cases of AIS showed amplification of EVI1, SKIL, and MUC4. In contrast, ECT2, EIF5A2, PIK3CA, and TNFSF10 showed no amplification in AIS. Additionally, 51 advanced lung adenocarcinomas, giving a total of 83 adenocarcinomas, were also examined by qPCR. Altogether, seven cases (8%) were amplified at ECT2, seven (8%) at EIF5A2, nine (11%) at PIK3CA, and eight (10%) at TNFSF10 (Fig. 1b).
Affiliation: Department of Pathology, Graduate School of Comprehensive Human Sciences, University of Tsukuba, Ibaraki, Japan.